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Background: Toxoplasma gondii infects all warm-blooded animals, including humans. Early diagnosis and determining
the infective stage are critical for effectively treating immunosuppressed individuals and pregnant women with
toxoplasmosis. Among the rhoptry proteins of the parasite, Rhoptry protein 8 (ROP8), is known to be expressed during
the early stages of T. gondii infection and is involved in parasitophorous vacuole formation. In this study, we have
investigated the diagnostic efficacy of recombinant ROP8 (rROP8).
Methods: The ROP8 gene was cloned into pCOLD I DNA vector and expressed as a soluble recombinant antigen in
Escherichia coli. Expressed ROP8 protein was evaluated using western blot method.
Results: Western blot analysis of purified rROP8 antigen using 200 T. gondii-infected human serum samples, as well as
non-infected serum controls, allowed for the successful identification of toxoplasmosis-positives, yielding a 90% sensitivity
and 94% specificity.
Conclusion: Our findings indicated that rROP8 antigen expressed in E. coli was able to detect toxoplasmosis in infected
human serum with specificity and sensitivity suggesting that rROP8 antigen represents a valid diagnostic marker for
toxoplasmosis.
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Toxoplasma gondii is an obligate intracellular parasite that
infects about one third of the human population [1-3]. The
incidence of T. gondii infection varies based on geograph-
ical location due to environmental conditions, cultural
habits, and hygiene standards [2,4,5]. Although acute toxo-
plasmosis is typically asymptomatic in HIV/AIDS patients,
chronic infection in immunocompromised individuals can
lead to life threatening encephalitis [6,7]. In addition, toxo-
plasmosis is known to cause severe complications in preg-
nant women, including miscarriage.
Commercially available serological kits for the diagnosis
of toxoplasmosis are usually based on total antigens isolated
from in vivo or in vitro cultured T. gondii. Notably, produc-
tion of these antigens is expensive, and they commonly* Correspondence: lauyeeling@um.edu.my
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article, unless otherwise stated.contain host cell-derived contaminants [8-10]. In addition,
the use of live parasites during antigen preparation can lead
to health risks. In order to overcome these limitations, re-
combinant DNA technology has been employed for the
production of antigens [11,12]. In fact, the use of this cost
effective method allows for the purification of stage-specific
T. gondii antigens, which can be used to differentiate acute
and chronic infections [13]. In this regard, many antigenic
genes from T. gondii have recently been cloned and
expressed using various systems. Also, several reports have
described the successful use of recombinant antigenic pro-
teins to detect antibodies against T. gondii [8,11,14-19].
These previous studies analyzed recombinant antigens both
individually and in combination to increase diagnostic
sensitivity.
Among the rhoptry antigens, rhoptry protein 2
(ROP2) family proteins have been extensively studied.
Rhoptry protein 8 (ROP8), which is a member of the
ROP2 family, is expressed in both tachyzoites andntral Ltd. This is an Open Access article distributed under the terms of the
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volved in host cell invasion as well as parasitophorous
vacuole membrane (PVM) formation [21]. Therefore,
several rhoptry antigens (ROP1, 2, 8, 16, and 18) have
been tested as potential vaccine candidates. While ROP1
and ROP2 were evaluated with regard to serological de-
tection of T. gondii-infected serum samples, ROP8 has
not been assessed as a diagnostic candidate. Therefore,
in the present study, we have expressed recombinant
ROP8 (rROP8) and investigated its efficacy as a diagnos-
tic marker for toxoplasmosis in humans.
Methods
Parasite
The tachyzoites of T. gondii were propagated using HFF
cells that were cultured and maintained in complete
DMEM medium (2 mM glutamine supplemented with
10% (v/v) FBS, 5 μg/ml streptomycin and 5 U/ml peni-
cillin) at 37°C with 5% CO2. The parasites were egressed
out of the host cells by passing through a 25 G needle
and purified using a 3 μm pore size polycarbonate mem-
brane filter. The tachyzoites were harvested by centrifu-
ging at 300 g for 15 min and suspended in appropriate
buffer prior to use.
Recombinant plasmid constructions
The genomic DNA of tachyzoites (RH strain) was iso-
lated using TriZol reagents (Invitrogen, USA). The
ROP8 gene (Genbank ID: AF011377) was amplified from
the genomic DNA using gene specific primers (forward
primer 5’CCCAAGCTTAGCATGGAATTTTCTGTGT
TACG 3’ and reverse primer 5’ CGGAATTCTCATGCC
GGTTCTCCATCAG 3’containing the HindIII and
EcoR1 restriction sites as italicized). The PCR product
was purified and cloned into the pCOLD I DNA vector
plasmid at the specified restriction site. The resulting re-
combinant construct was transformed into BL21 (DE3)
E. coli expression host cells. Recombinant clones were
screened and verified by DNA sequencing.
Expression of recombinant protein
A single colony of fresh transformant of the recombin-
ant construct was inoculated in 5 ml of Luria Bertani
(LB) broth with Ampicillin (100 mg/ml) and Chloram-
phenicol (34 mg/ml) and grown overnight at 37°C, with
250 rpm shaking. From the overnight culture, 0.1% of
the inoculum was inoculated in 10 ml of LB and grown
until an OD600 of 0.5 to 0.6 was reached. At this point
the culture was maintained at 15°C for 30 min and IPTG
was added to a final concentration of 1 mM. The culture
was grown overnight at 15°C. The cells were harvested
by centrifugation at 10,000 rpm for 10 min and sub-
jected to protein purification.Purification of recombinant protein ROP8
The histidine tagged recombinant protein was purified
through native purification system (Invitrogen, USA) using
nickel nitrilotriacetic acid (Ni-NTA) (Qiagen, USA). Briefly,
the cell pellet was suspended in binding buffer and solubi-
lized by sonication on ice using a high intensity pulse for 15
mins. The lysate was then separated by centrifugation at
10,000 rpm for 30 min and incubated with Ni-NTA resin
for 3 h at room temperature. The resin was washed with
binding buffer containing increasing concentrations of
Immidazole (5, 10 and 15 mM) to remove all contaminat-
ing proteins. The recombinant protein was eluted at
200 mM immidazole concentration. The purity of the pro-
teins was analysed by running a 12% SDS-PAGE. The con-
centration of the purified recombinant proteins was
estimated by the Bradford method (Bio-Rad, USA) and
stored at −80°C in aliquots till further use.
Western blot analysis of ROP8 recombinant protein
Proteins were separated according to their molecular
weight using a 12% SDS-PAGE gel. The proteins on the
gel were transferred to a polyvinylidene difluoride
(PVDF) membrane (Bio-Rad, USA). The membrane was
blocked with blocking agent (5% non-fat milk powder in
TBS) and washed three times with TBS and TBS-T for
5 min. This was followed by incubation with primary
antibody (1:250) in 2.5% blocking agent in TBS for 2 h
at room temperature and subjected to washing. The
membrane was then incubated with anti-Human IgG
(1:2500) for 1 h with shaking, washed and incubated
with SAAP (1:2500) for 1 h. Finally, the membrane was
washed and the protein was detected using nitro blue
tetrazolium/bromochloroindolyl phosphate (NBT/BCIP)
as the substrate.
Analysis of ROP8 protein sensitivity and specificity
Purified rROP8 were evaluated in Western blot assays
using serum samples from three groups of human toxo-
plasmosis cases. Group 1 consisted of patients with early
acute toxoplasmosis (IgM positive, IgG negative; n = 25);
Group 2, consisted of patients with acute toxoplasmosis
(IgM positive, IgG positive; n = 30); Group 3, consisted
of patients with chronic toxoplasmosis (IgM negative,
IgG positive; n = 50) and Group 4, consisted of toxoplas-
mosis negative control healthy human serum samples
(IgM negative, IgG negative; n = 100). These samples
were obtained from the Diagnostic Laboratory at the
Department of Parasitology, University of Malaya, and
grouped based on Captia™ Toxoplasma gondii IgG and
Toxoplasma gondii IgM kits (Trinity Biotech, Ireland).
Specificity of the recombinant protein was also tested
with sera of patients diagnosed as having different
infections, namely, amoebiasis (2 samples), cysticercosis
(4 samples), filariasis (3 samples), and toxocariasis
Table 1 Summary of western blot results obtained from
recombinant rhoptry protein 8 detected with human
serum samples




No. % No. %
1 (early acute: IgG−, IgM+) 25 23 90 2 10
2 (acute: IgG+, IgM+) 30 23 92 3 8
3 (chronic: IgG+, IgM−) 50 41 82 9 18
4 (toxoplasmosis negative:
IgG−, IgM−)
100 6 6 94 94
Other infections
Amoebiasis 2 0 0 2 100
Cysticercosis 4 0 0 4 100
Filariasis 3 0 0 3 100
Toxocariasis 2 0 0 2 100
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specificity of rROP8 protein was calculated and tabulated
in Table 1. Sensitivity was calculated as (number of true
positive results)/(number of true positive results + number
of false-negative results), and specificity was calculated as
(number of true negative results)/(number of true negative
results + number of false-positive results).Figure 1 SDS-PAGE analysis of expression of rROP8 in pCOLD I DNA v
with Toxoplasmosis -infected patient serum. Lane 1 is rROP8 protein, Lane
the expression of rROP8 protein at approximately 67 kDa.Results
Cloning of the ROP8 gene into the pCOLD I DNA vector
The ROP8 gene (1728 bp) was amplified from tachyzoite
genomic DNA and successfully cloned into the pCOLD
I DNA vector. Positive colonies were confirmed by poly-
merase chain reaction (PCR) and sequencing using
gene-specific primers. Sequencing results revealed 100%
similarity with the previously published ROP8 gene se-
quence. Finally, the verified recombinant plasmid was
transformed into the BL21 (DE3) expression host.
Expression and purification of rROP8
Expression of rROP8 protein was induced with 1 mM
IPTG for 24 h. SDS-PAGE was subsequently performed to
analyze the expressed rROP8, which appeared as an intense
67 kDa band that was absent from the negative control
(vector only) (Figure 1A and 1B). The rROP8 protein was
successfully purified under native conditions using Ni-NTA
resin (Figure 2A). Purification of rROP8 was verified by
western blot with both His tag-specific antibody (anti-His)
and human serum from a Toxoplasma-infected patient
(Figure 2B). In each case a 67 kDa band was observed,
while nothing was detected in the vector control lane.
Reactivity of human serum samples against rROP8
protein
Toxoplasma-infected human serum samples were used
to evaluate the sensitivity and specificity of rROP8 as aector. (A) Coomassie brilliant blue stained, (B) Western blot probed
2 is vector control (pCOLD I DNA vector protein only). Arrow indicates
Figure 2 SDS analysis of purified rROP8. (A) Coomassie brilliant blue stained, (B) Western blot probed with Toxoplasmosis patient serum. Lane 1
and 2 are rROP8 protein. Lane 3 is vector control (pCOLD I DNA vector protein). Arrow indicates the purified rROP8 protein at approximately 67 kDa.
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combinant protein was tested against three different in-
fected serum groups: early acute (IgG−, IgM+), acute
(IgM+, IgG+), and chronic (IgG+, IgM−). Non-infected
human serum samples were employed as a negative con-
trol. In addition, rROP8 was tested against human sera
corresponding to other non-Toxo parasitic infections,
such as toxocariasis, filariasis, amoebiasis, and cysticer-
cosis. We observed that rROP8 protein yielded the fol-
lowing sensitivities with regard to serological detection
of T. gondii: 90% (23 of 25) for early acute, 92% (23 of
30) for acute, and 82% (41 of 50) for chronic infections
(Table 1). Four positive results for each group are shownFigure 3 Detection of rROP8 with patient sera infected by Toxoplasmo
from each category. Four samples from each category are shown here. Lanes
IgM+), lane 5 to 8 represents results of group 2 serum samples (acute: IgG+, I
IgG+, IgM−), lanes 13 to 16 represents results of group 4 serum samples(toxoin (Figure 3). Considering the 100 toxoplasmosis-
negative human serum samples, six samples were found
to react with rROP8, yielding a specificity of 94% (6 of
100) (Table 1). None of the non-Toxo parasitic infection
sera reacted with rROP8 protein.
Discussion
In the present study, the ROP8 gene was successfully
cloned into a bacterial expression vector (pCOLD I DNA),
and rROP8 protein was expressed in BL21 (DE3) host cells.
One-step metal affinity chromatography was subsequently
performed to purify rROP8, producing a low amount of
pure recombinant protein per liter of bacterial culture.sis. Each Western Blot strip of the purified rROP8 was tested with serum
1 to 4 represents results of group 1 serum samples (early acute IgG−,
gM+), lane 9 to 12 represents results of group 3 serum samples (chronic:
plasmosis negative: IgG−, IgM−) as a control group.
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than other antigens that we have previously expressed and
purified in our laboratory. Nevertheless, we retrieved suffi-
cient quantities of rROP8 for testing its value as a diagnos-
tic marker.
We tested the reactivity of three distinct groups of
toxoplasmosis-infected human sera (i.e., early acute, acute,
and chronic phase samples) against rROP8 by western blot
(Table 1). Importantly, we observed no rROP8 cross re-
activity when analyzing sera from other parasitic infections
(i.e., amoebiasis, cysticercosis, filariasis and toxocariasis).
We found that purified rROP8 antigen showed high sensi-
tivity and specificity for the diagnosis of toxoplasmosis. In
fact, our western blot analysis revealed a specificity of 96%
and sensitivity for detecting IgG of 90%. This sensitivity
was slightly higher when compared to ROP1 antigen, which
was recently investigated with regard to the detection and
differentiation of acute and chronic phase toxoplasmosis
[22]. In addition, Van Gelder (along with other groups)
evaluated recombinant ROP2 expressed in E. coli, as a
marker for detection of T. gondii-specific antibodies in sera
and found that recombinant ROP2 antigen detected IgG in
89 out of 98 toxoplasmosis-positive samples. A similar
study was performed by Martin, who observed a sensitivity
of 91% when using E. coli-expressed ROP2 to detect
toxoplasmosis-specific IgG in human serum samples [23].
The major finding of this study is that rROP8 antigen
represents a valid diagnostic marker for detecting toxo-
plasmosis via western blot assay. Notably, the western
blot method is thought to be better than enzyme-linked
immunosorbent assay (ELISA), especially considering
that the likelihood of obtaining false positive results by
western blot is much lower as compared to ELISA [24].
The superiority of the western blot assay over ELISA for
screening human serum samples has also been con-
firmed in other studies. In fact, immunoblot was found
to be more informative and less affected by sample deg-
radation than ELISA, producing high confidence results
that could be directly visualized [25]. Thus, given its
high specificity and sensitivity, we have selected to use
the western blot technique to evaluate the efficacy of
rROP8 as a diagnostic marker for toxoplasmosis.
Our rROP8-related findings might be valuable for fu-
ture development of diagnostic kits based on the
immmunochromatographic test (ICT). The ICT repre-
sents the best serological assay for diagnosing infections,
including toxoplasmosis compared to ELISA, although
ELISA is more commonly used and considered to be
simpler than other tests. Nevertheless, the ICT is more
rapid, efficient, accurate, and low cost than ELISA [26].
In addition, ICT is advantageous because it can be used
in the field (e.g., diagnosis of farm animals) [26].
One of the limitations of this study is failure to follow up
with a repeat serology test on a second sample from thesame patient to confirm the acute infection. By standard
practice, early acute infection is confirmed by repeat sam-
pling between 7–15 days and observing the IgG conversion
[1]. Repeated sampling was not feasible in this study as pa-
tients were discharged immediately after treatment.
Conclusion
Our findings demonstrate that rROP8 produced in
E. coli can be used as an antigen for the detection of
toxoplasmosis-specific antibodies (IgG and IgM) by
western blot assay. Thus, rROP8 represents a valid
diagnostic marker for differentiating between the dis-
tinct stages of toxoplasmosis infection. In fact, the
rROP8 based detection method yielded a 90% sensitivity
and 94% specificity. Thus, rROP8 may represent a use-
ful candidate antigen for the development of a novel
ICT assay to detect toxoplasmosis. Furthermore, the
ROP8 gene could be considered for future toxoplasmo-
sis vaccine development.
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